SPS Healthcare Ltd is a privately owned company based in London UK, and is developing gentle, non-surgical treatments for skin malignancies.

Lead agent: Bleosome™ - a novel liposomal formulation to treat basal cell carcinoma (BCC)

Bleosome™ is a novel, patented liposomal formulation of an approved drug which allows it to be applied topically to skin cancers.  Basal cell carcinoma (BCC) is the most common form of skin cancer, accounting for at least 32% of all cancers globally. Global incidence of BCC was 5,884,759 in 2017, a rise of 77.4% since 1990. Whilst not life-threatening, untreated BCC is disfiguring and locally destructive to surrounding tissues.  The incidence of BCC is linked to sun exposure, hence most BCCs occur on the face. Surgical excision is the standard of care for BCC, leading to facial scarring and severe impact on patients' quality of life, hence many patients refuse surgery. The burden on the NHS for diagnosing and treating BCC is huge, with around 1 in 4 primary care consultations related to skin conditions, and 35-60% of dermatology referrals related to skin lesions. There is a therefore a significant public health need for an effective topical treatment that provides patients with an alternative to surgery, and provides healthcare providers with a far more cost-effective, low risk treatment regimen to offer patients. The cost associated with treating non-melanoma skin cancers in the USA is estimated to be greater than $US 400 million.

Bleosome™ has been tested on 60 BCC patients who refused surgery with a >90% cure rate by clinical observation. Biopsy studies to confirm clinical observations are underway and being prepared for publication.  Treatment was painless and no adverse effects were observed.

A Phase 2 clinical trial is planned for 2023/4 to compare Bleosome™ with a marketed product.

For all investor enquiries, please contact Dr Sunil Chopra on +44 (0)7891 505495 or via email: sunil.chopra @ spshealthcare.co.uk